Structure-activity relationships governing mammalian SWI/SNF chromatin remodeling activity as a function of chromatin state

控制哺乳动物 SWI/SNF 染色质重塑活动的结构-活性关系作为染色质状态的函数

基本信息

  • 批准号:
    10377992
  • 负责人:
  • 金额:
    $ 67.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Recent whole-exome sequencing studies in human cancer and neurodevelopmental disorders have unmasked frequent mutations in genes encoding chromatin regulatory proteins. Specifically, genes encoding subunits of the mammalian SWI/SNF ATP-dependent chromatin remodeling complexes (also called mSWI/SNF or BAF complexes) are perturbed in over 20% of malignancies, underscoring their critical roles in the maintenance of timely and appropriate gene expression. The mechanisms by which mSWI/SNF family complexes are targeted on chromatin and the features of the histone landscape that govern their activities remain unknown. Indeed, a systematic evaluation defining the contributions of specific histone landscape features to canonical BAF, PBAF, and non-canonical BAF complex targeting and activity would represent a significant advancement in the field at- large. Here we aim to: (1) Determine the genome-wide targeting of distinct, final-form mSWI/SNF complexes in human cells and the impact of select cancer-associated complex perturbations; (2) Define the in vitro nucleosome remodeling and ATPase activities of endogenously-purified mSWI/SNF subcomplexes, BAF, PBAF, and ncBAF, in wild-type (WT) and mutant states; and (3) Determine the impact of core histone variants and histone tail modifications on mSWI/SNF complex nucleosome binding and activity. Taken together, successful completion of these aims centered at the intersection of biochemistry, epigenetics, and cancer biology, will constitute a highly timely series of advances in the field of chromatin biology, and will contribute important knowledge regarding the mechanism of targeting of mSWI/SNF complexes across a range of both normal and oncogenic states. Given that a major impediment to the development of on-target modulatory agents of mSWI/SNF complexes lies in the lack of biological understanding of complex-specific targeting and functional regulation, the results of this proposal are likely to provide the basis for new approaches toward targeted disruption of mSWI/SNF-chromatin interactions.
项目摘要 最近在人类癌症和神经发育障碍中的全外显子组测序研究揭示了 编码染色质调节蛋白的基因频繁突变。具体地,编码以下亚基的基因 哺乳动物SWI/SNF ATP依赖性染色质重塑复合物(也称为mSWI/SNF或BAF 复合物)在超过20%的恶性肿瘤中受到干扰,强调了它们在维持恶性肿瘤中的关键作用。 及时和适当的基因表达。靶向mSWI/SNF家族复合物的机制 对染色质和组蛋白景观的特点,管理他们的活动仍然是未知的。确实 系统评价定义特定组蛋白景观特征对典型BAF,PBAF, 和非典型的BAF复合物的靶向和活性将代表该领域的重大进展, 大.在这里,我们的目标是:(1)确定不同的,最终形式的mSWI/SNF复合物的全基因组靶向, 人类细胞和选择的癌症相关的复杂扰动的影响;(2)定义体外 内源性纯化的mSWI/SNF亚复合物,BAF,PBAF, 和ncBAF,在野生型(WT)和突变状态;和(3)确定核心组蛋白变体的影响, 组蛋白尾部修饰对mSWI/SNF复合物核小体结合和活性的影响。综合来看,成功 这些目标的完成集中在生物化学、表观遗传学和癌症生物学的交叉点上, 构成了染色质生物学领域的一个非常及时的系列进展,并将作出重要贡献 关于mSWI/SNF复合物在一系列正常和 致癌状态考虑到开发靶向调节剂的主要障碍, 目前对mSWI/SNF复合物的研究主要在于缺乏对复合物特异性靶向和功能的生物学理解, 监管,该提案的结果可能会为实现有针对性的新方法提供基础 破坏mSWI/SNF-染色质相互作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Cigall Kadoch其他文献

Cigall Kadoch的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Cigall Kadoch', 18)}}的其他基金

The Center for Synovial Sarcoma Biology and Therapeutics
滑膜肉瘤生物学和治疗中心
  • 批准号:
    10797558
  • 财政年份:
    2023
  • 资助金额:
    $ 67.66万
  • 项目类别:
The Center for Synovial Sarcoma Biology and Therapeutics
滑膜肉瘤生物学和治疗中心
  • 批准号:
    10600538
  • 财政年份:
    2022
  • 资助金额:
    $ 67.66万
  • 项目类别:
Structure-activity relationships governing mammalian SWI/SNF chromatin remodeling activity as a function of chromatin state
控制哺乳动物 SWI/SNF 染色质重塑活动的结构-活性关系作为染色质状态的函数
  • 批准号:
    10596560
  • 财政年份:
    2021
  • 资助金额:
    $ 67.66万
  • 项目类别:
Structure-activity relationships governing mammalian SWI/SNF chromatin remodeling activity as a function of chromatin state
控制哺乳动物 SWI/SNF 染色质重塑活动的结构-活性关系作为染色质状态的函数
  • 批准号:
    10184885
  • 财政年份:
    2021
  • 资助金额:
    $ 67.66万
  • 项目类别:
Cancer-Specific Targeting and Function of Mammalian SWI/SNF (BAF) Chromatin Remodeling Complexes
哺乳动物 SWI/SNF (BAF) 染色质重塑复合物的癌症特异性靶向和功能
  • 批准号:
    10112848
  • 财政年份:
    2019
  • 资助金额:
    $ 67.66万
  • 项目类别:
Cancer-Specific Targeting and Function of Mammalian SWI/SNF (BAF) Chromatin Remodeling Complexes
哺乳动物 SWI/SNF (BAF) 染色质重塑复合物的癌症特异性靶向和功能
  • 批准号:
    10359214
  • 财政年份:
    2019
  • 资助金额:
    $ 67.66万
  • 项目类别:
Cancer-Specific Targeting and Function of Mammalian SWI/SNF (BAF) Chromatin Remodeling Complexes
哺乳动物 SWI/SNF (BAF) 染色质重塑复合物的癌症特异性靶向和功能
  • 批准号:
    10600847
  • 财政年份:
    2019
  • 资助金额:
    $ 67.66万
  • 项目类别:
Cancer-Specific Targeting and Function of Mammalian SWI/SNF (BAF) Chromatin Remodeling Complexes
哺乳动物 SWI/SNF (BAF) 染色质重塑复合物的癌症特异性靶向和功能
  • 批准号:
    9898333
  • 财政年份:
    2019
  • 资助金额:
    $ 67.66万
  • 项目类别:
The Center for Synovial Sarcoma Biology and Therapeutics
滑膜肉瘤生物学和治疗中心
  • 批准号:
    10381956
  • 财政年份:
    2018
  • 资助金额:
    $ 67.66万
  • 项目类别:
Reversing Oncogenic BAF Complex Structure & Function: New Therapeutic Approaches
逆转致癌 BAF 复杂结构
  • 批准号:
    8757471
  • 财政年份:
    2014
  • 资助金额:
    $ 67.66万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 67.66万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 67.66万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 67.66万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.66万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 67.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 67.66万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 67.66万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 67.66万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 67.66万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 67.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了